Concepedia

Author

Gautam Borthakur

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

Borthakur, Gautam, Borthakur,Gautam, G Borthakur, G. Borthakur, Gautam Borthakur, Gautam M. Borthakur, San Francisco

1.6K

Publications

36.5K

Citations

92

H-Index

105

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center
GB

About

Gautam Borthakur is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

49

140

7.4K

2

Health Sciences

34

68

4K

3

Engineering

2

2

73

4

Blood Transplantation

2

2

268

5

Natural Sciences

1

1

19

Gautam Borthakur

×

479

Publications

31.5K

Citations

89

H-Index

YearCitations

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>

Daniel J. Klionsky, Amal Kamal Abdel‐Aziz, Sara Abdelfatah,

Autophagy

2021

2.5K

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

Rongqing Pan, Leah J. Hogdal, Juliana M. Benito,

Cancer Discovery

2013

717

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson,

New England Journal of Medicine

2019

491

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri,

Journal of Clinical Oncology

2009

412

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald,

Blood

2013

373

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

Jörge E. Cortes, Hagop M. Kantarjian, James M. Foran,

Journal of Clinical Oncology

2013

358

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

Farhad Ravandi, Jörge E. Cortes, Daniel M. Jones,

Journal of Clinical Oncology

2010

355

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

Farhad Ravandi, Susan O’Brien, Deborah Thomas,

Blood

2010

343

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

Roland B. Walter, Megan Othus, Gautam Borthakur,

Journal of Clinical Oncology

2011

339

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

Jo Ishizawa, Sarah F. Zarabi, R. Eric Davis,

Cancer Cell

2019

339

Page 1